Associations between patterns of neuroendocrine liver metastatic burden and outcomes after liver-directed therapy, systemic chemotherapy and peptide receptor radionuclide therapy
{{output}}
Introduction Patients with liver-dominant metastatic neuroendocrine tumor (NET) have multiple treatment options. Post hoc analysis of NETTER-1 suggested that tumor size but not tumor burden predicted progression-free survival (PFS), contrary to prior publicati... ...
